Brief: Urogen Announces Positive Data From Pivotal Olympus Trial Evaluating Jelmyto In Patients With Low-Grade Upper Tract Urothelial Cancer
15/05/2020 14:49
May 15 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN ANNOUNCES POSITIVE DATA FROM PIVOTAL OLYMPUS TRIAL
EVALUATING JELMYTO™ IN PATIENTS WITH LOW-GRADE UPPER TRACT
UROTHELIAL CANCER
Source text for Eikon: ID:nBw3sL8bwa
Further company coverage: UR8.F
(Reuters.Briefs@thomsonreuters.com)
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors